Moderna

This article needs constant updating and more deep contents

Moderna   (Big pharma)
Formation	2010
Founder	•  Noubar Afeyan •  Kenneth R. Chien •  Robert S. Langer •  Derrick Rossi
Headquarters	Massachusetts, USA
Staff	820
Interests	Vaccine/RNA Vaccine, “COVID-19/Vaccine”
Interest of	Charles Hoffe, Bob Langer
Subpage	•Moderna/CEO
Membership	•  Moncef Slaoui •  Stéphane Bancel •  Stephen Hoge •  Juan Andres •  Marcello Damiani •  Tracey Franklin •  Lori Henderson •  Ray Jordan •  David Meline •  Tal Zaks
Spooky tech company producing cure-all RNA vaccines

For the vaccine, see Moderna COVID-19 vaccine

Moderna (formerly ModeRNA) is an American biotech company focused on drug discovery and drug and vaccine development based exclusively on messenger RNA (mRNA). In April 2020, Trump appointed Moderna board member Moncef Slaoui to Operation Warp Speed, the plan to vaccinate the entire American population by 2021. In November 2020, the company launched its Covid-19 vaccine.

History

In 2010, ModeRNA Therapeutics was formed to commercialize the research of stem cell biologist Derrick Rossi, who developed a method for modifying mRNA, transfecting it into human cells, then dedifferentiating it into stem cells that could then be further dedifferentiated into desired target cell types.

Moderna has also received considerable U.S. government funding ($438 million) from the Biomedical Advanced Research and Development Authority (BARDA), a division of HHS overseen by HHS’ Assistant Secretary for Preparedness and Response (ASPR) Robert Kadlec. Moderna has also stated that it is directly collaborating with the U.S. government to bring its vaccine candidate to market.

Moderna’s regulatory success has also been result of backing that it received in January 2020 from the Coalition for Epidemic Preparedness Innovations (CEPI), which was founded in 2017 by the governments of Norway and India along with the World Economic Forum (WEF) and the Bill and Melinda Gates Foundation. Moderna’s Covid-19 vaccine has also received additional millions from long-time Moderna backer Bill Gates.

In April 2020, Gates authored an article where he described Moderna’s mRNA vaccine for Covid-19 as the “most exciting” and discussed it at length, writing "It’s a bit like building your computer system and your first piece of software at the same time."

The company has worked with BARDA for an improved Zika virus vaccine candidate, and DARPA for advancing mRNA therapies and vaccines for biodefense.

In December 2018, Moderna became the largest biotech initial public offering (IPO) in history, raising $600 million for 8% of its shares, implying an overall valuation of $7.5 billion. Fitting for its military/intelligence ties, the company has a reputation for secrecy and little of its work has ever been published, and none peer-reviewed or scientifically validated.

Covid-19 Vaccine

Full article: Moderna COVID-19 vaccine

Moderna states on its website, under the heading The ‘Software of Life’:

When we have a concept for a new mRNA medicine and begin research, fundamental components are already in place.

Generally, the only thing that changes from one potential mRNA medicine to another is the coding region – the actual genetic code that instructs ribosomes to make protein. Utilizing these instruction sets gives our investigational mRNA medicines a software-like quality. We also have the ability to combine different mRNA sequences encoding for different proteins in a single mRNA investigational medicine.

We are leveraging the flexibility afforded by our platform and the fundamental role mRNA plays in protein synthesis to pursue mRNA medicines for a broad spectrum of diseases.

Executives Selling Shares

Under a rule put in place by the Securities and Exchange Commission in 2000 to allow company employees to sell shares without facing insider-trading charges, several Moderna (and fellow Big Pharma Pfizer) executives have - legally - sold shares worth more than $100 million during the summer and autumn 2020. Since January, CEO Stéphane Bancel has sold roughly $40 million worth of Moderna stock held by himself or associated investment funds; Chief Medical Officer Tal Zaks, the medical face outwards of the US company and of the key figures in the development of its Covid-19 vaccine, has sold around $60 million; and President Stephen Hoge has sold more than $10 million.

"On a scale of one to 10, one being less concerned and 10 being the most concerned," said Daniel Taylor, an associate professor of accounting at the Wharton School, "this is an 11."

In July 2021, Tal Zak left the company and sold most of his remaining shares. Per August 23, he only had 1,5 million dollars in shares left. Also Bancel keeps selling down.

People

Since 2011, Moderna has been led by CEO Stéphane Bancel, a French businessman who is not a scientist and comes from a pharma sales and operations background.

After Noubar Afeyan and Robert Langer, Bancel is the largest individual shareholder in the company.

Stephen Hoge is President and a former McKinsey & Company management consultant who joined in 2012; he is the fourth-largest individual shareholder in the company.

Lorence Kim is CFO and a former Goldman Sachs biotech investment banking managing director who joined in 2014; he is the fifth-largest individual shareholder in the company.

Since 2011, the Chairman of Moderna has been the CEO of Flagship Pioneering, businessman Noubar Afeyan. Afeyan holds his interest in Moderna through various Flagship Pioneering vehicles, however, at the 2018 IPO, documents filed stated that Afeyan owned 19.5% of the company, while Flagship owned 18%, thus giving Afeyan control over 37.5% of the company.

Dr. Tal Zaks, an Israeli citizen who began his career at GlaxoSmithKline, oversaw “preclinical development, clinical development and regulatory affairs” for Moderna and all of its subsidiaries until he left the company in July 2021.

 

Related Quotations

Page	Quote	Author	Date
Dominic Cummings	“In March [2020] I started getting calls from various people saying these new mRNA vaccines could well smash the conventional wisdom. [. . .] People like Bill Gates and that kind of network were saying. [. . .] Essentially what happened is, [. . .] there is a network of people, Bill Gates type people, who were saying completely rethink the paradigm of how you do this.. What Bill Gates and people like that were saying to me and others in number 10 was you need to think of this much more like the classic programs of the past. [. . .] the Manhattan Project in WWII, the Apollo program.. But what Bill Gates and people were saying [. . .] was, the actual expected return on this is so high that even if does turn out to be all wasted billions it's still a good gamble [. . .] and that is what we did.”	Dominic Cummings	May 2021
Charles Hoffe	“In a single dose of a Moderna vaccine, there are 40 trillion messenger RNA molecules...Three-quarters of these molecules leave the arm of the injection, circulate through the bloodstream, and end up in the tiny capillary vessels. These little packages of the genes are absorbed into the cells around the blood vessels of the vascular endothelium. The packages open, the genes are released, your body then gets to work reading these genes and manufacturing trillions and trillions of COVID spike proteins. Hoffe said even though there are 40 trillion mRNA genes, each gene can produce “many, many COVID spike proteins. And the purpose of the spike proteins is that your body recognizes this as a foreign protein and will make antibodies against it so that you’re then protected against COVID.” But this antibody response comes at a heavy price, he said. “The spike protein…becomes part of the cell wall of ….these cells that line your blood vessels, which are supposed to be smooth so that your blood flows smoothly. Now you have these little spiky bits sticking out,” Hoffe said. From here, “blood platelets circulate in your vessels…to detect a damaged vessel and block that vessel to stop bleeding. So when the platelet comes through the capillary, it suddenly hits all these little COVID spikes that are jutting into the inside of the vessel. It is absolutely inevitable that a blood clot will form.” Hoffe claimed the clots are “too small and too scattered” to show up on CT scans, angiograms, or MRIs, but are numerous enough to cause damage. There’s some tissues in your body like intestine and liver and kidneys that can regenerate to quite a good degree. But brain and spinal cord and heart muscle and lungs do not. When they’re damaged, it’s permanent, like all these young people who are now getting myocarditis from these shots. They have permanently damaged hearts. This is the terrifying concern. And not only is the long-term outlook very grim, but with each successive shot, the damage will add and add and add. It’s going to be cumulative.”	Charles Hoffe

 

Known members

2 of the 10 of the members already have pages here:

Member	Description
Stéphane Bancel	French CEO of Moderna who struck it rich with its first product allowed on the market, a COVID-19 vaccine
Moncef Slaoui	Responsible for warp-speed development of experimental Covid-19 jabs up to January 2021. Fired over a "substantiated" sexual harassment claim in March 2021.

Many thanks to our Patrons who cover ~2/3 of our hosting bill. Please join them if you can.